AAPL327.47+5.81 (+1.81%) ▲|ABBV259.24+2.32 (+0.90%) ▲|ABT102.42+1.67 (+1.66%) ▲|ACN144.04+5.30 (+3.82%) ▲|ADBE219.40+7.23 (+3.41%) ▲|AMAT547.41-15.40 (-2.74%) ▼|AMD524.18-15.51 (-2.87%) ▼|AMGN376.75+5.25 (+1.41%) ▲|AMT169.27+4.62 (+2.80%) ▲|AMZN232.83-0.84 (-0.36%) ▼|AVGO382.28-10.19 (-2.60%) ▼|AXP321.64-19.21 (-5.63%) ▼|BA209.29+0.06 (+0.03%) ▲|BAC61.83+0.55 (+0.90%) ▲|BKNG175.37+2.54 (+1.47%) ▲|BLK1,040.77+3.61 (+0.35%) ▲|BMY62.21+0.70 (+1.14%) ▲|BNY159.46-0.66 (-0.41%) ▼|BRK-B492.57+1.72 (+0.35%) ▲|C132.69+0.81 (+0.61%) ▲|CAT896.48+1.94 (+0.22%) ▲|CL90.86+0.78 (+0.86%) ▲|CMCSA22.28+0.36 (+1.64%) ▲|COF200.25+0.29 (+0.14%) ▲|COP120.68+0.48 (+0.40%) ▲|COST929.68+3.62 (+0.39%) ▲|CRM161.23+4.30 (+2.74%) ▲|CSCO112.76-0.01 (0.00%) ▼|CVS107.83+0.94 (+0.88%) ▲|CVX194.68+0.26 (+0.13%) ▲|DE613.86+3.84 (+0.63%) ▲|DHR192.21-0.29 (-0.15%) ▼|DIS94.57+1.74 (+1.87%) ▲|DUK130.10+0.84 (+0.65%) ▲|EMR147.10+2.20 (+1.52%) ▲|FDX316.56+0.94 (+0.30%) ▲|GD386.17+4.38 (+1.15%) ▲|GE356.21+7.21 (+2.06%) ▲|GEV1,020.28-10.91 (-1.06%) ▼|GILD129.86-1.01 (-0.77%) ▼|GM82.69+2.02 (+2.50%) ▲|GOOG322.10+3.76 (+1.18%) ▲|GOOGL322.24+4.55 (+1.43%) ▲|GS1,069.88-4.84 (-0.45%) ▼|HD325.84+1.13 (+0.35%) ▲|HON243.71-2.56 (-1.04%) ▼|IBM211.32+4.67 (+2.26%) ▲|INTC96.19-4.04 (-4.03%) ▼|INTU290.04+8.51 (+3.02%) ▲|ISRG335.65+3.63 (+1.09%) ▲|JNJ261.61+2.34 (+0.90%) ▲|JPM350.56+0.66 (+0.19%) ▲|KO81.40+0.23 (+0.28%) ▲|LIN509.87+3.55 (+0.70%) ▲|LLY1,197.81+11.94 (+1.01%) ▲|LMT580.77+12.18 (+2.14%) ▲|LOW204.11+2.19 (+1.08%) ▲|LRCX311.77-8.01 (-2.50%) ▼|MA534.88+4.59 (+0.87%) ▲|MCD264.06+1.26 (+0.48%) ▲|MDLZ59.99-0.06 (-0.10%) ▼|MDT82.78+0.77 (+0.94%) ▲|META604.36-1.74 (-0.29%) ▼|MMM170.75+1.16 (+0.68%) ▲|MO72.73+0.65 (+0.90%) ▲|MRK130.24-0.24 (-0.18%) ▼|MS214.04-1.14 (-0.53%) ▼|MSFT381.95+0.37 (+0.10%) ▲|MU929.06-61.16 (-6.18%) ▼|NEE88.94-0.85 (-0.95%) ▼|NFLX69.20+0.31 (+0.45%) ▲|NKE41.00+0.01 (+0.02%) ▲|NOW95.93+3.99 (+4.34%) ▲|NVDA207.41-1.35 (-0.65%) ▼|ORCL117.31-2.73 (-2.27%) ▼|PEP134.99+0.04 (+0.03%) ▲|PFE24.55-0.04 (-0.14%) ▼|PG147.08+1.20 (+0.82%) ▲|PLTR122.85-0.52 (-0.42%) ▼|PM193.77+2.65 (+1.39%) ▲|QCOM167.40-3.71 (-2.17%) ▼|RTX211.72+2.56 (+1.22%) ▲|SBUX104.47+1.26 (+1.22%) ▲|SCHW101.77+0.16 (+0.15%) ▲|SO97.50+0.90 (+0.93%) ▲|SPG227.65+2.45 (+1.09%) ▲|T23.61+0.65 (+2.83%) ▲|TMO562.62-9.70 (-1.69%) ▼|TMUS177.36+6.94 (+4.07%) ▲|TSLA315.64-4.05 (-1.27%) ▼|TXN279.89-5.10 (-1.79%) ▼|UBER68.75-0.17 (-0.24%) ▼|UNH423.17-0.39 (-0.09%) ▼|UNP303.11-1.22 (-0.40%) ▼|UPS114.05-0.05 (-0.04%) ▼|USB63.65+0.32 (+0.51%) ▲|V353.23+1.63 (+0.46%) ▲|VZ45.06+1.24 (+2.82%) ▲|WFC86.24+0.05 (+0.06%) ▲|WMT108.88+0.48 (+0.44%) ▲|XOM157.22+0.33 (+0.21%) ▲|AAPL327.47+5.81 (+1.81%) ▲|ABBV259.24+2.32 (+0.90%) ▲|ABT102.42+1.67 (+1.66%) ▲|ACN144.04+5.30 (+3.82%) ▲|ADBE219.40+7.23 (+3.41%) ▲|AMAT547.41-15.40 (-2.74%) ▼|AMD524.18-15.51 (-2.87%) ▼|AMGN376.75+5.25 (+1.41%) ▲|AMT169.27+4.62 (+2.80%) ▲|AMZN232.83-0.84 (-0.36%) ▼|AVGO382.28-10.19 (-2.60%) ▼|AXP321.64-19.21 (-5.63%) ▼|BA209.29+0.06 (+0.03%) ▲|BAC61.83+0.55 (+0.90%) ▲|BKNG175.37+2.54 (+1.47%) ▲|BLK1,040.77+3.61 (+0.35%) ▲|BMY62.21+0.70 (+1.14%) ▲|BNY159.46-0.66 (-0.41%) ▼|BRK-B492.57+1.72 (+0.35%) ▲|C132.69+0.81 (+0.61%) ▲|CAT896.48+1.94 (+0.22%) ▲|CL90.86+0.78 (+0.86%) ▲|CMCSA22.28+0.36 (+1.64%) ▲|COF200.25+0.29 (+0.14%) ▲|COP120.68+0.48 (+0.40%) ▲|COST929.68+3.62 (+0.39%) ▲|CRM161.23+4.30 (+2.74%) ▲|CSCO112.76-0.01 (0.00%) ▼|CVS107.83+0.94 (+0.88%) ▲|CVX194.68+0.26 (+0.13%) ▲|DE613.86+3.84 (+0.63%) ▲|DHR192.21-0.29 (-0.15%) ▼|DIS94.57+1.74 (+1.87%) ▲|DUK130.10+0.84 (+0.65%) ▲|EMR147.10+2.20 (+1.52%) ▲|FDX316.56+0.94 (+0.30%) ▲|GD386.17+4.38 (+1.15%) ▲|GE356.21+7.21 (+2.06%) ▲|GEV1,020.28-10.91 (-1.06%) ▼|GILD129.86-1.01 (-0.77%) ▼|GM82.69+2.02 (+2.50%) ▲|GOOG322.10+3.76 (+1.18%) ▲|GOOGL322.24+4.55 (+1.43%) ▲|GS1,069.88-4.84 (-0.45%) ▼|HD325.84+1.13 (+0.35%) ▲|HON243.71-2.56 (-1.04%) ▼|IBM211.32+4.67 (+2.26%) ▲|INTC96.19-4.04 (-4.03%) ▼|INTU290.04+8.51 (+3.02%) ▲|ISRG335.65+3.63 (+1.09%) ▲|JNJ261.61+2.34 (+0.90%) ▲|JPM350.56+0.66 (+0.19%) ▲|KO81.40+0.23 (+0.28%) ▲|LIN509.87+3.55 (+0.70%) ▲|LLY1,197.81+11.94 (+1.01%) ▲|LMT580.77+12.18 (+2.14%) ▲|LOW204.11+2.19 (+1.08%) ▲|LRCX311.77-8.01 (-2.50%) ▼|MA534.88+4.59 (+0.87%) ▲|MCD264.06+1.26 (+0.48%) ▲|MDLZ59.99-0.06 (-0.10%) ▼|MDT82.78+0.77 (+0.94%) ▲|META604.36-1.74 (-0.29%) ▼|MMM170.75+1.16 (+0.68%) ▲|MO72.73+0.65 (+0.90%) ▲|MRK130.24-0.24 (-0.18%) ▼|MS214.04-1.14 (-0.53%) ▼|MSFT381.95+0.37 (+0.10%) ▲|MU929.06-61.16 (-6.18%) ▼|NEE88.94-0.85 (-0.95%) ▼|NFLX69.20+0.31 (+0.45%) ▲|NKE41.00+0.01 (+0.02%) ▲|NOW95.93+3.99 (+4.34%) ▲|NVDA207.41-1.35 (-0.65%) ▼|ORCL117.31-2.73 (-2.27%) ▼|PEP134.99+0.04 (+0.03%) ▲|PFE24.55-0.04 (-0.14%) ▼|PG147.08+1.20 (+0.82%) ▲|PLTR122.85-0.52 (-0.42%) ▼|PM193.77+2.65 (+1.39%) ▲|QCOM167.40-3.71 (-2.17%) ▼|RTX211.72+2.56 (+1.22%) ▲|SBUX104.47+1.26 (+1.22%) ▲|SCHW101.77+0.16 (+0.15%) ▲|SO97.50+0.90 (+0.93%) ▲|SPG227.65+2.45 (+1.09%) ▲|T23.61+0.65 (+2.83%) ▲|TMO562.62-9.70 (-1.69%) ▼|TMUS177.36+6.94 (+4.07%) ▲|TSLA315.64-4.05 (-1.27%) ▼|TXN279.89-5.10 (-1.79%) ▼|UBER68.75-0.17 (-0.24%) ▼|UNH423.17-0.39 (-0.09%) ▼|UNP303.11-1.22 (-0.40%) ▼|UPS114.05-0.05 (-0.04%) ▼|USB63.65+0.32 (+0.51%) ▲|V353.23+1.63 (+0.46%) ▲|VZ45.06+1.24 (+2.82%) ▲|WFC86.24+0.05 (+0.06%) ▲|WMT108.88+0.48 (+0.44%) ▲|XOM157.22+0.33 (+0.21%) ▲|
25.9 C
New York
Friday, July 24, 2026

Tag: eye disease

newssourceFORcompanyinformationcontent1releasesmarket

Preservative-Free Eye Drops Market Size to reach US$1.67 billion in 2031 | CAGR of 4.3% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global preservative-free eye drops market is growing...

Preservative-Free Eye Drops Market Size to reach US$1.67 billion in 2031 | CAGR of 4.3% | Exclusive Report by The Insight Partners

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global preservative-free eye drops market is growing...

MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and Pipeline Advancements | DelveInsight

While the current MCR therapy market is dominated by high-value, niche indications, the emerging pipeline is positioned to expand the class into mainstream disorders....

MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and Pipeline Advancements | DelveInsight

While the current MCR therapy market is dominated by high-value, niche indications, the emerging pipeline is positioned to expand the class into mainstream disorders....

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies

Refresh Releases First of its Kind Eye Drop for Dry Eyes

Refresh Advanced OMEGA-3 Lubricant Eye Drops are the first eye drops on the market with omega-3 fatty acids MONTREAL, July 11, 2025 /CNW/ - AbbVie...

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and granted an aggregate of 77,875 restricted stock unit (“RSU”) awards to 46 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt...

BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy

Orally administered treatment was well tolerated, with early signs of clinical activityIn models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEye disease

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers